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ORIGINAL ARTICLE
Vaccination with Mycobacterium bovis BCG Strains Danish
and Pasteur in White-tailed Deer (Odocoileus virginianus)
Experimentally Challenged with Mycobacterium bovis
M. V. Palmer, T. C. Thacker and W. R. Waters
National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA, USA
Impacts
• Bovine tuberculosis is an important zoonotic disease, for which most
industrialized nations have eradication programmes.
• A serious obstacle to many eradication programmes worldwide is the
presence of wildlife reservoirs of Mycobacterium bovis. Vaccination is one
tool that may mitigate transmission from wildlife to domestic animals.
• Vaccination of white-tailed deer with M. bovis BCG Danish or Pasteur
decreases disease severity; however, vaccine persists within tissues for as
long as 250 days, can induce lesions in regional lymph nodes and can be
transmitted between vaccinated and non-vaccinated deer.
Introduction
Mycobacterium bovis is the causative agent of tuberculosis
in animals and has one of the broadest host ranges of any
pathogen. Mycobacterium bovis can cause tuberculosis in
humans clinically indistinguishable from disease caused
by M. tuberculosis. Public health concerns posed by
potential transmission of M. bovis from cattle to humans
prompted many countries to implement national
programmes to eradicate tuberculosis from cattle. Most
eradication campaigns have been successful in decreasing
the prevalence of bovine tuberculosis. However, in spite
of long-standing and costly efforts, some countries have
found it impossible to eradicate bovine tuberculosis. One
obstacle responsible for many faltering eradication
campaigns has been the presence of a wildlife reservoir of
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Summary
Wildlife reservoirs of Mycobacterium bovis represent serious obstacles to the
eradication of tuberculosis in domestic livestock and the cause for many falter-
ing bovine tuberculosis eradication programmes. One approach in dealing with
wildlife reservoirs of disease is to interrupt inter-species and intraspecies trans-
mission through vaccination of deer or cattle. To evaluate the efficacy of BCG
vaccination in white-tailed deer, 35 deer were assigned to one of three groups;
one s.c. dose of 107 CFU of M. bovis BCG Pasteur (n = 12); 1 s.c. dose of
107 CFU of M. bovis BCG Danish (n = 11); or unvaccinated deer (n = 12).
After vaccination, deer were inoculated intratonsilarly with virulent M. bovis.
Lesion severity scores of the medial retropharyngeal lymph node, as well as all
lymph nodes combined, were reduced in vaccinated deer compared to unvacci-
nated deer. BCG Danish vaccinated deer had no late stage granulomas charac-
terized by coalescent caseonecrotic granulomas containing numerous acid-fast
bacilli compared to BCG Pasteur vaccinated or unvaccinated deer where such
lesions were present. Both BCG strains were isolated as late as 250 days after
vaccination from deer that were vaccinated but not challenged. In white-tailed
deer, BCG provides protection against challenge with virulent M. bovis.
Issues related to vaccine persistence, safety and shedding remain to be further
investigated.
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M. bovis infection. In most cases, wildlife originally
acquired tuberculosis from cattle; however, the disease is
now spilling back from wildlife to cattle, impeding the
progress of eradication (Daszak et al., 2000; Miller and
Kaneene, 2006). In an effort to mitigate wildlife to cattle
transmission of M. bovis, some countries are investigating
the possible role of vaccination.
In 1994, a free-ranging white-tailed deer (Odocoileus
virginianus) in Michigan was diagnosed with tuberculosis
caused by M. bovis (Schmitt et al., 1997). Subsequent
surveys identified a focus of M. bovis infection in free-
ranging white-tailed deer in northeast Michigan (O’brien
et al., 2001, 2002). This represented the first known reser-
voir of M. bovis in free-ranging wildlife in the United
States and a significant impediment to the ongoing effort
to eradicate bovine tuberculosis from domestic livestock.
At least 44 cattle herds on 39 different farms (five herds
have been infected twice) in Michigan have been diag-
nosed with tuberculosis since the discovery of tuberculosis
in free-ranging deer, presumably from direct or indirect
contact with infected deer. Control and surveillance
measures have now been in place in Michigan for over
10 years and a significant reduction in apparent preva-
lence of tuberculosis in deer has been achieved (O’brien
et al., 2006). Current disease control measures include
decreasing deer density through increased hunting and
strict control of feeding and baiting of white-tailed deer.
However, hunter support for further population reduc-
tion is waning and public resentment of control measures
has grown (O’brien et al., 2006). A control measure that
could be applied to specific areas of sustained high dis-
ease prevalence is vaccination of deer to prevent infection,
disease, or transmission. Recently, protection has been
demonstrated by parenteral vaccination of white-tailed
deer with M. bovis bacillus Calmette Guerin (BCG) Pas-
teur and oral vaccination of white-tailed deer with BCG
Danish (Palmer et al., 2007; Nol et al., 2008). Mycobacte-
rium bovis BCG was first used as an anti-tuberculosis vac-
cine in humans in 1921 and is one of the oldest and
most widely used vaccines in the world today (Fine,
1989). Since its discovery, propagation of M. bovis at vari-
ous laboratories has resulted in numerous strains that dif-
fer morphologically and genetically. Reports of vaccine
efficacy in humans vary widely by geographical region
and among different age groups; however, consistent pro-
tection has only been observed against miliary tuberculo-
sis and tuberculous meningitis in neonates. The great
variability in efficacy is attributed to one or more factors
including differences in vaccine strains (Fine, 1989).
The purpose of this study was to evaluate the protec-
tive efficacy of both BCG Danish and BCG Pasteur
administered parenterally using a model of intratonsilar
inoculation of white-tailed deer. BCG Danish and Pasteur
are both considered late strains in relation to the original
attenuated strain produced by Albert Calmette and
Camille Guerin; however, these strains have been shown
to differ genetically (Brosch et al., 2007). In particular,
BCG Danish belongs to a group of BCG strains consid-
ered to be the most attenuated (Brosch et al., 2007).
Materials and Methods
Animals, vaccination and challenge
Thirty-five white-tailed deer (1 year old, 20 castrated
males and 15 females) were obtained from a captive
breeding herd (tuberculosis- and paratuberculosis-free) at
the National Animal Disease Center (Ames, IA, USA). All
deer were housed and cared for according to institutional
guidelines. Deer were randomly assigned to one of three
groups; one dose of 107 colony-forming units (CFU)
M. bovis BCG Pasteur (n = 12); one dose of 107 CFU
M. bovis BCG Danish (n = 11); or unvaccinated deer
(n = 12). Deer were vaccinated SC on the right side of
the neck, midway between the head and shoulder. One
hundred twenty days after vaccination all but 3 deer from
each group were inoculated intratonsilarly, as described
previously, with approximately 495 CFU of virulent
M. bovis strain 1315 (NADC designation) into each tonsi-
lar crypt for a total dose of 990 CFU (Palmer et al.,
1999). To evaluate vaccine persistence within tissues, 3
non-vaccinated deer and 3 each of BCG Pasteur and
BCG Danish vaccinated deer were not challenged, but
maintained and examined at the termination of the study
(vaccinated, non-challenged deer, n = 9).
Strain 1315, used for challenge, was originally isolated
from a white-tailed deer in Michigan. For challenge inoc-
ulation, deer were anaesthetized by IM injection of a
combination of xylazine (2 mg/kg) (Mobay Corporation,
Shawnee, KS) and ketamine (6 mg/kg) (Fort Dodge Labo-
ratories, Fort Dodge, IA). After inoculation, the effects of
xylazine were reversed by IV injection of tolazoline
(4 mg/kg) (Lloyd Laboratories, Shenandoah, IA). Vacci-
nated and unvaccinated deer were housed together in an
outdoor paddock prior to challenge with virulent M. bovis,
at which time they were moved to appropriate animal
housing. Experimental infection was done inside a bio-
safety level 3 (BL-3) building with personnel wearing
appropriate personal protective equipment, including full-
face respirators with HEPA filtered canisters to prevent
exposure to aerosolized M. bovis. The BL-3 animal hous-
ing had negative air pressure compared to the outside.
Airflow was such that air was pulled out of animal rooms
towards a central corridor, preventing air exchange
between rooms. Airflow was adjusted to produce 11.4 air
changes per hour. Deer were housed 4 per pen and fed
a commercial pelleted feed with free access to water.
Efficacy of BCG Vaccination in White-tailed Deer M. V. Palmer et al.
No claim to original US government works
244 Journal compilation ª 2009 Blackwell Verlag • Zoonoses Public Health. 56 (2009) 243–251
All procedures were approved by the National Animal
Disease Center Institutional Animal Care and Use
Committee.
Challenge inoculum and vaccines
The M. bovis BCG strains as well as the challenge strain
M. bovis 1315 were grown in Middlebrook’s 7H9 media
supplemented with 10% oleic acid-albumin-dextrose
complex (Difco, Detroit, MI) plus 0.05% Tween 80
(Sigma Chemical Co., St. Louis, MO) as described (Bolin
et al., 1997). Mid log-phase growth bacilli were pelleted
by centrifugation at 750 · g, washed twice with phosphate
buffered saline (PBS) (0.01 M, pH 7.2) and diluted to
the appropriate cell density in 2 ml of PBS. Bacilli
were enumerated by serial dilution plate counting on
Middlebrook’s 7H11 selective media (Becton Dickinson,
Cockeysville, MD). A single vaccine dose consisted of
107 CFU M. bovis BCG in 1.5 ml PBS.
Necropsy and tissue sampling
One hundred thirty days after challenge with virulent
M. bovis (i.e. 250 days after vaccination) all deer were
euthanized by IV sodium pentobarbital. At necropsy, the
following tissues were collected and processed for isola-
tion of M. bovis and microscopic analysis as described
(Palmer et al., 2002a): palatine tonsil; lung; liver; mandib-
ular, parotid, medial retropharyngeal, tracheobronchial,
mediastinal, hepatic, mesenteric, superficial cervical and
prefemoral lymph nodes. Two hundred fifty days after
vaccination, vaccinated but not challenged deer were also
euthanized and tissues collected as described above for
M. bovis BCG isolation and microscopic analysis.
Lymph nodes were cross-sectioned at 0.5 cm intervals
and examined. Each lung lobe was examined separately
and cross-sectioned at 0.5 to 1.0 cm intervals. Lungs and
lymph nodes were subjected to semi-quantitative scoring
of gross lesions adapted from Vordermeier et al. (Vor-
dermeier et al., 2002). Lung lobes (left cranial, left caudal,
right cranial, right caudal, middle and accessory) were
subjected to the following scoring system: (0) no visible
lesions; (1) no external gross lesions, but lesions seen
upon slicing; (2) <5 gross lesions of <10 mm in diameter;
(3) >5 gross lesions of <10 mm in diameter; (4) >1 dis-
tinct gross lesion of >10 mm in diameter; (5) coalescing
gross lesions. Scoring of lymph node gross lesions was
based on the following scoring system: (0) no visible
lesions; (1) small focal lesion (1–2 mm in diameter); (2)
several small foci; (3) extensive lesions. Tissues collected
for microscopic analysis were fixed by immersion in 10%
neutral buffered formalin and included all tissues col-
lected for bacteriological examination. For microscopic
examination, formalin-fixed tissues were processed by
routine paraffin-embedment techniques, cut to 5 lm sec-
tions and stained with hematoxylin and eosin (HE). Adja-
cent sections were cut from samples containing lesions
suggestive of tuberculosis (caseonecrotic granulomas) and
stained by the Ziehl-Neelsen technique for identification
of acid-fast bacteria (AFB). Microscopic lesions were
graded (stages I-IV) according to criteria adapted from
that described by Rhoades et al. (Rhoades et al., 1997).
Stage I (initial) granulomas are characterized by accumu-
lations of epithelioid macrophages admixed with low
numbers of lymphocytes and neutrophils. Multinucleated
giant cells may be present but necrosis is absent. Acid-fast
bacilli, when present, are seen within macrophages or mul-
tinucleated giant cells. Stage II (solid) granulomas are char-
acterized by accumulations of epithelioid macrophages
surrounded by a thin connective tissue capsule. Infiltrates
of neutrophils and lymphocytes may be present at the
granuloma periphery as well as multinucleated giant cells.
Necrosis when present is minimal. Stage III (necrotic)
granulomas are characterized by complete fibrous encap-
sulation. Necrotic cores are surrounded by a zone of epi-
thelioid macrophages admixed with multinucleated giant
cells and lymphocytes. Stage IV (necrotic and mineral-
ized) granulomas are characterized by a fibrous capsule
surrounding irregular multicentric granulomas with
multiple necrotic cores. Necrotic cores contain foci of
dystrophic mineralization. Epithelioid macrophages and
multinucleated giant cells surround necrotic areas and
there are often moderate to marked infiltrates of lympho-
cytes. Acid-fast bacilli are often present in moderate num-
bers and primarily located within the caseum of the
necrotic core.
Isolation and identification of mycobacterial isolates
Tissues were processed for isolation of M. bovis as previ-
ously described (Palmer et al., 2002b). Isolates of M. bovis
were identified by colony morphology, growth, and bio-
chemical characteristics as well as by PCR. PCR was used
to confirm M. bovis from tissues collected at necropsy
and to distinguish virulent M. bovis from BCG Danish or
BCG Pasteur. BCG was identified by the absence of RD1
using the primers ET1, ET2 and ET3 from Talbot et al.,
(1997) following the reaction and thermocycler condi-
tions described below. BCG was further characterized
using PCR using a technique similar to that of Talbot
et al., (1997) which exploits regions of difference between
the strains. BCG strain Danish was differentiated from
strain Pasteur using the following primers: RDDen1-
CAGGCTAGTTGCCAACACATT (forward); RDDen2-AT
GTGTGGGCTGTGTGCTAA (forward); RDDen3-CGCA
GGTTAACAGCAGTTTG (reverse). Primer setup and
M. V. Palmer et al. Efficacy of BCG Vaccination in White-tailed Deer
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interpretation are described in Table 1 using the reaction
and thermocycling conditions described below.
Putative mycobacterial isolates visible on Middlebrook
7H10 or Middlebrook 7H11 media were transferred to
25 ll of sterile Tris-EDTA (TE) buffer using a sterile-dis-
posable inoculation loop. When £10 colonies were pres-
ent, all isolates were collected and examined separately.
When >10 colonies were present, a minimum of 10% of
the colonies present were collected and examined sepa-
rately. The bacterial suspension was heat inactivated at
80C for 10 min and heated for an additional 10 min.
One microlitre of the bacterial preparation was added to
the following PCR master mix: 1· PCR Reaction Buffer
with MgCl2 (Roche Applied Science, Indianapolis, IN,
USA), 50 pm of each primer, 200 lm of each dNTP (PCR
Nucleotide Mix, Roche Applied Science), 2 U FastStart
Taq (Roche Applied Science), 5 lg BSA (Ambion, Austin,
TX, USA) in a total reaction volume of 50 ll. Touch-
down PCR was performed with an initial preheating step
of 2 min at 94C followed by denaturation at 94C for
45 s, annealing started at 65C for 1 min with a 1C
decrease per cycle followed by extension at 72C for
2 min, after the annealing temperature reached 50C, an
additional 29 cycles were performed. A final extension at
72C for 10 min was included. Samples were analysed by
electrophoresis on 1.5% agarose gel and visualized with
ethidium bromide.
Isolates of acid fast bacteria that were not identified by
PCR as virulent M. bovis or M. bovis BCG were further
identified using 16S ribosomal DNA sequencing as
described previously (Kierschner and Bottger, 1998).
Sequences were then identified through the use of a myco-
bacterial species sequence database (Harmsen et al., 2003).
Statistical analysis
Mean group values for lesion scores were compared using
an unpaired Student’s t-test with Welch’s correction for
non-parametric data to compensate for the lack of
homoscedascity (GraphPad Prism, GraphPad Software,
San Diego, CA, USA). A P-value <0.05 was considered
significant.
Results
Mycobacterium bovis challenged deer, vaccinated
and non-vaccinated
In non-vaccinated deer, the most common site for lesion
development after challenge was the medial retropharyn-
geal lymph node (n = 4) while in BCG Pasteur vaccinated
deer, the most common sites for lesions were the medial
retropharyngeal and tracheobronchial lymph nodes
(n = 2 each). In BCG Danish vaccinated deer, lesions
were not seen in the medial retropharyngeal lymph node
and the most common sites for lesions were the tracheo-
bronchial and mesenteric lymph nodes (n = 2 each),
followed by lung (n = 1).
Gross lesion severity scores of the medial retropharyn-
geal lymph node individually as well as all lymph nodes
examined combined were lower (P < 0.05 and P < 0.1,
respectively), in BCG Danish vaccinated deer than in
non-vaccinated deer, but not different from BCG Pasteur
vaccinated deer (Fig. 1). In both groups of BCG









RDDen1, RDDen3 NP 1090 260
RDDen2, RDDen3 260 260 NP
NP, no product.
Fig. 1. Gross lesion severity scores from medial retropharyngeal
lymph node (a) or all lymph nodes examined combined (b) of unvacci-
nated deer or deer vaccinated s.c. with 1 · 107 CFU Mycobacterium
bovis BCG Pasteur or 1 · 107 CFU M. bovis BCG Danish and chal-
lenged intratonsilarly with 990 CFU of virulent M. bovis. Values repre-
sent the mean gross lesion severity score ± SE. Scoring system: (0) no
visible lesions; (1) small focal lesion (1–2 mm in diameter); (2) several
small foci; (3) extensive lesions.
Efficacy of BCG Vaccination in White-tailed Deer M. V. Palmer et al.
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vaccinated deer, lung lesion scores were lower than, but
not significantly different from those of non-vaccinated
deer (data not shown).
Microscopic evaluation of the medial retropharyngeal
lymph nodes revealed a lack of granulomas in BCG Dan-
ish vaccinated deer, whereas granulomas of all histological
stages (I–IV) were seen in medial retropharyngeal lymph
nodes from non-vaccinates and BCG Pasteur vaccinated
deer. In the lung, microscopic granulomas of all stages
(I–IV) were seen in non-vaccinates. Stage IV microscopic
granulomas were not seen in the lungs of BCG Danish or
BCG Pasteur vaccinated deer; however, stages I–III were
present.
Virulent M. bovis was isolated from 6/9 unvaccinated
deer, 3/8 Danish vaccinated deer and 2/9 Pasteur vacci-
nated deer (Table 2). Regardless of treatment group, viru-
lent M. bovis was most commonly isolated from the
medial retropharyngeal lymph node, followed by the tra-
cheobronchial lymph node, tonsil and lung. BCG Danish
was isolated from 4/8 Danish vaccinated deer, with the
mediastinal lymph node, tracheobronchial lymph node
and superficial cervical lymph nodes being the most com-
mon sites of isolation. BCG Pasteur was isolated from the
mediastinal lymph node of two BCG Danish vaccinated
deer and both the mediastinal and hepatic lymph nodes
of a third BCG Danish vaccinated deer (Table 2). Like-
wise, BCG Pasteur was isolated from 4/9 BCG Pasteur
vaccinated deer with the mediastinal lymph node, tra-
cheobronchial lymph node and superficial cervical lymph
nodes being the most common sites of isolation. BCG
vaccine strains were not isolated from control non-vacci-
nated deer challenged with M. bovis. Non-tuberculous
mycobacteria were isolated from 5 deer. Mycobacterium
terrae was isolated from 1/9 non-vaccinated deer and 1/8
BCG Danish vaccinated deer. Mycobacterium septicum was
isolated from 1/9 non-vaccinated deer and 1/9 BCG Pas-
teur vaccinated deer. Mycobacterium avium was isolated
from 1/9 BCG Pasteur vaccinated deer (Table 2). Lesions
were not seen in tissues from which non-tuberculous
mycobacteria were isolated. In one BCG Pasteur vacci-
nated deer, virulent M. bovis, BCG Pasteur and M. avium
were all isolated from a non-lesioned tracheobronchial
lymph node.
Vaccinated, non-challenged deer
In vaccinated, non-challenged deer (three from each treat-
ment group, n = 9) gross lesions consistent with tubercu-
losis were not seen (Table 3). In one BCG Danish
vaccinated deer microscopic granulomas were seen in the
superficial cervical, tracheobronchial and hepatic lymph
nodes. In a second BCG Danish vaccinated deer, micro-
scopic lesions were seen in the superficial cervical lymph
node only. In one BCG Pasteur vaccinated deer micro-
scopic granulomas were seen in the hepatic lymph node.
In all cases, granulomas were of stages II–III (Fig. 2).
BCG Danish was recovered from all three Danish vacci-
nated deer, while BCG Pasteur was recovered from 2/3
Pasteur vaccinated deer. PCR and 16S ribosomal DNA
sequencing revealed an isolate from the hepatic lymph
Table 2. Summary of gross lesions, microscopic lesions and bacterio-
logical isolation of Mycobacterium bovis from white-tailed deer vacci-
nated with either BCG Danish or BCG Pasteur and challenged by






Gross lesions 4/9 1/8 2/9
Microscopic lesions 4/9 5/8 3/9
Isolation of virulent M. bovis 6/9 3/8 2/9
Isolation of M. bovis BCG Danish 0/9 4/8 0/9
Isolation of M. bovis BCG Pasteur 0/9 3/8 4/9
Isolation of both BCG Danish and
Pasteur from same animal
0/9 1/8 0/9






Deer from which M. bovis was
not isolated





dDeer from which neither virulent M. bovis nor M. bovis BCG was
isolated and lesions were not seen.
Table 3. Summary of gross lesions, microscopic lesions and bacterio-
logical isolation of Mycobacterium bovis BCG from white-tailed deer







Gross lesions 0/3 0/3 0/3
Microscopic lesions 0/3 2/3a 1/3b
Isolation of M. bovis BCG Danish 0/3 3/3c 0/3
Isolation of M. bovis BCG Pasteur 0/3 0/3 2/3d
Isolation of BCG from
tissues with lesions
0/3 1/3 0/3
aSuperficial cervical lymph node from one deer; tracheobronchial,
hepatic and superficial cervical lymph node from a second deer.
bHepatic lymph node from one deer.
cTracheobronchial and mediastinal lymph nodes from one deer; hepa-
tic, superficial cervical and mediastinal lymph nodes from a second
deer; superficial cervical lymph node from a third deer.
dSuperficial cervical lymph node from one deer; lung from a second
deer.
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node of one BCG Danish vaccinated deer to be consistent
with an unknown mycobacterial species. Neither BCG
vaccine strains nor non-tuberculous mycobacteria were
recovered from non-vaccinated, non-challenged control
animals.
Discussion
Previous studies have shown that BCG Danish and BCG
Pasteur can effectively decrease disease severity in experi-
mentally challenged white-tailed deer (Palmer et al., 2007;
Nol et al., 2008). However, a novel finding in this study
was persistence of both Danish and Pasteur vaccine
strains within host tissues for 250 days after vaccination.
Moreover, vaccine-induced microscopic lesions and dis-
semination of vaccine to multiple sites was seen in at least
1 deer from each vaccinated group. Vaccine persistence
within host tissues is an important safety concern in ani-
mals that may be consumed for food. In red deer, M. bovis
BCG Pasteur was still present in tissues from the site of
injection as well as the draining lymph nodes in 2/6 and
3/6 deer, respectively, 3 months after s.c. vaccination with
2 · 106 CFU of M. bovis BCG Pasteur (Slobbe et al.,
1999). Lesions in regional lymph nodes and shedding of
vaccine have not been features of studies involving red
deer (Griffin et al., 1993) or cattle. In this study, unlike
red deer, BCG not only persisted in vaccinated deer, but
spread to multiple sites, was associated with microscopic
granulomas and in the case of BCG Pasteur vaccinated
deer, was shed, transmitted and later isolated from 3/8
deer vaccinated with BCG Danish. It is interesting to note
the apparent shedding and transmission of BCG Pasteur,
but not BCG Danish. It is possible that this observation
reflects increased shedding of vaccine from Pasteur vacci-
nated deer. Alternatively, both vaccines may be shed, but
environmental survivability may be decreased in BCG
Danish compared to BCG Pasteur.
Vaccine persistence presents an interesting challenge.
While a significant safety concern with food producing
animals, persistence of BCG within host tissue is neces-
sary for development of an effective immune response.
Studies in mice demonstrate persistence of M. bovis BCG
for up to 30 weeks and spread to distant organs after s.c.
vaccination (Olsen et al., 2004; Aldwell et al., 2006). Mur-
ine studies further show that persistence of M. bovis BCG
is vital in sustaining long-lasting immunological memory.
Vaccinated mice receiving chemotherapy to eliminate
residual post-vaccinal BCG demonstrated inferior cell-
mediated immune responses and inferior protection
against challenge with virulent M. tuberculosis as mea-
sured by colonization of the spleen by M. tuberculosis
when compared to mice still harboring low numbers of
BCG (Olsen et al., 2004; Cross et al., 2007).
Persistence of vaccine strains within tissues also high-
lights the need for careful identification of mycobacterial
isolates in vaccine efficacy studies. Studies relying on bac-
teriological culture to measure vaccine-induced protection
could be misleading if isolates of BCG are mistakenly
identified as virulent M. bovis. Traditional culture meth-
ods, without further biochemical or nucleic acid based
analysis cannot differentiate BCG from virulent M. bovis.
The importance of careful identification of mycobacte-
rial isolates is further supported by isolation of non-
tuberculous mycobacteria from several deer. This finding
also illustrates the ubiquitous nature of environmental
mycobacteria and their ability to colonize susceptible
hosts. Absence of lesions supports their non-pathogenic
nature in deer. Isolation of non-tuberculous mycobacteria
underscores the challenges posed by exposure to
saprophytic non-tuberculous mycobacteria present in the
environment. Environmental exposure of red deer or
white-tailed deer to environmental saprophytic mycobac-
teria did not influence susceptibility to experimental
infection with M. bovis (Griffin et al., 1999; Palmer et al.,
2007). The number of affected deer in this study is too
low to reach any conclusions concerning a positive or
negative effect of colonization with environmental myco-
bacteria on vaccine efficacy. However, studies in cattle
have shown that sensitization of calves to environmental
saprophytic mycobacteria adversely affects the protective
efficacy of BCG vaccination (Buddle et al., 2002). Simi-
larly, one explanation for the highly variable efficacy
observed in human vaccine trials has been exposure to
saprophytic environmental mycobacteria (Brandt et al.,
2002). Vaccination of neonatal calves has been used as a
Fig. 2. Section of superficial cervical lymph node from deer vacci-
nated SC with 1 · 107 CFU of Mycobacterium bovis BCG Danish and
examined 250 days later. Note vaccine-induced granulomas composed
of central necrotic, mineralized cores, epithelioid macrophages and
multinucleated giant cells. H/E. Bar = 250 lm.
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strategy to avoid prior sensitization by saprophytic envi-
ronmental mycobacteria. Indeed, vaccination of neonatal
calves induces a higher level of immunity than that seen
in calves vaccinated at 5–6 months of age (Buddle et al.,
2003a,b; Hope et al., 2005). A similar strategy could be
feasible for vaccination of captive white-tailed deer, but
would be problematic for vaccination of free-ranging
white-tailed deer.
Comparative genomic analysis of numerous BCG
strains has demonstrated various deletions and duplica-
tions that distinguish one BCG strain from another.
Although both BCG Danish and Pasteur are categorized
as late strains in relation to the original BCG isolates,
BCG Pasteur has deletions in regions RD14 and RD15;
regions that are present in BCG Danish. BCG Pasteur is
also unique among BCG strains in containing a duplica-
tion of a region known as DU1 (Brosch et al., 2007). In
this study, gross lesion scores were decreased in both
Danish and Pasteur vaccinated deer indicating vaccine
induce protection. These findings are consistent with pre-
vious work with BCG vaccinated white-tailed deer (Pal-
mer et al., 2007; Nol et al., 2008). Studies in cattle
examining the comparative efficacy of BCG Danish and
Pasteur showed that both strains protected cattle equally
well from intratracheal challenge with virulent M. bovis
(Wedlock et al., 2007). In this study, some measures of
protection suggested BCG Danish provided superior pro-
tection to that conferred by BCG Pasteur. Specifically, in
the medial retropharyngeal lymph node, BCG Danish pre-
vented the development of advanced granulomas in a
fashion superior to that seen in Pasteur vaccinates.
Advanced stage IV lesions are characterized by multiple
coalescent granulomas with extensive necrosis and
numerous intralesional acid-fast bacilli (Palmer et al.,
2007). Such advanced lesions increase the likelihood of
disease dissemination within the host and disease trans-
mission between hosts. A vaccine that prevents advanced
lesion development, while not preventing infection or dis-
ease, is likely to decrease bacterial shedding and disease
transmission. In the intratonsilar model of inoculation
used in this study, the most common site for lesion
development is the medial retropharyngeal lymph node
(Palmer et al., 1999, 2002a, 2007). Therefore, it is particu-
larly interesting that Danish vaccinates did not develop
lesions in the medial retropharyngeal lymph node. A sim-
ilar finding was observed in a recent study of BCG Dan-
ish vaccination in white-tailed deer (Nol et al., 2008).
Protection against experimental challenge has also been
observed in BCG Danish vaccinated cattle (Wedlock
et al., 2007). Given the demonstrated efficacy and the fact
that BCG Danish is currently approved for use in humans
(Wedlock et al., 2007), BCG Danish may afford a viable
option for vaccination of deer.
It is doubtful that parenteral vaccination, such as that
used in this study, would be possible with free-ranging
wildlife on a large scale. More likely, an oral vaccine such
as that currently used to vaccinate wildlife against rabies
would be necessary (Desmettre et al., 1990). Oral delivery
of BCG, while posing several challenges, has been shown
to be feasible and efficacious with white-tailed deer
(Miller et al., 1999; Nol et al., 2008). Lipid based prepara-
tions to protect live M. bovis BCG from the harmful
effects of the gastric environment have proven effective in
brushtail possum and white-tailed deer vaccination trials
(Aldwell et al., 2003; Nol et al., 2008).
Although the ultimate goal of any tuberculosis vaccina-
tion programme is to eradicate tuberculosis, a more
immediate aim is to reduce the rate of transmission
between susceptible hosts. Any tuberculosis vaccine con-
sidered for use in free-ranging white-tailed deer need not
protect animals against infection or disease. Disease trans-
mission and prevalence would decline if lesion severity
and bacterial shedding were decreased in vaccinated deer.
This study demonstrated reduced lesion severity in white-
tailed deer vaccinated with either BCG Danish or BCG
Pasteur and challenged with virulent M. bovis; however,
superior protection against advanced lesion formation
was seen in BCG Danish vaccinates.
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